Epidemiology of viral hepatitis among Iranian population--a viral marker study.
Our studies revealed that the incidence of viral hepatitis in Iran is more common than in the western countries. Although the incidence of hepatitis type A in the region is not thoroughly investigated, our first report on this disease in our region reveals an almost complete immunity among adults after 30 years of age. The incidence of HBsAg among our voluntary blood donors is 3.5%. If it is assumed that the incidence rate in the whole country is also 3.5%, then it is possible that there are one million HBsAg carriers among 35 million Iranians. These carriers constitute a major health problem in Iran. There is a good possibility that the HBsAg incidence rate in the other countries of the region is similarly high. Therefore it is highly recommended that control and preventive measures such as third generation HB teting of donated blood and blood products become mandatory. All HBsAg positive donors should be interviewed and informed that their blood contains an infectious agent and this must be carefully considered at the times of bleeding. Other high risk groups such as haemodialysis patients and staff and haemophiliacs also should be investigated as possible candidates for HB vaccination.
D000293:Adolescent; D000328:Adult; D000368:Aged; D000914:Antibodies, Viral / Q000032:analysis; D001782:Blood Donors; D002648:Child; D002675:Child, Preschool; D005260:Female; D006506:Hepatitis A / Q000453:epidemiology*; D006509:Hepatitis B / Q000453:epidemiology*; D006512:Hepatitis B Core Antigens / Q000032:analysis; D006514:Hepatitis B Surface Antigens / Q000032:analysis; D006513:Hepatitis B e Antigens / Q000032:analysis; D006801:Humans; D007223:Infant; D007231:Infant, Newborn; D007492:Iran; D008297:Male; D008875:Middle Aged; D006435:Renal Dialysis / Q000009:adverse effects
D000914:Antibodies, Viral; D006512:Hepatitis B Core Antigens; D006514:Hepatitis B Surface Antigens; D006513:Hepatitis B e Antigens